Price Alert

Ensysce Biosciences Inc. (ENSC)

NASDAQ: ENSC · Real-Time Price · USD

2.09

0.04 (1.95%)

At close: Aug 18, 2025, 3:59 PM

2.10

0.45%

After-hours: Aug 18, 2025, 06:30 PM EDT

1.95% (1D)

Bid	2.01
Market Cap	4.95M
Revenue (ttm)	2.81M
Net Income (ttm)	-6.82M
EPS (ttm)	110.31
PE Ratio (ttm)	0.02
Forward PE	-43.2
Analyst	n/a

Ask	2.1
Volume	57,705
Avg. Volume (20D)	394,743
Open	2.06
Previous Close	2.05
Day's Range	2.04 - 2.09
52-Week Range	1.62 - 14.67
Beta	1.02

About ENSC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ENSC

Website n/a

Full Company Profile

Earnings Surprise

Ensysce Biosciences has released their quartely earnings on Aug 13, 2025:

Revenue of $1.37M exceeds estimates by $447.15K, with 654.14% YoY growth.

EPS of -0.79 exceeds estimates by 0.38, with 76.06% YoY growth.

Next Earnings Release

Ensysce Biosciences Inc. is scheduled to release its earnings on Nov 11, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+0.48%

ENSC stock has given up its prior gain. Ensysce Bi... Unlock content with Pro Subscription

2 weeks ago

+0.48%

Ensysce Biosciences shares are trading higher after the company announced it received FDA feedback for PF614-MPAR.

News

6 days ago · accessnewswire.com

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Approval Receives $5.3 Million Installment from NIDA To Support Overdose Prot...

2 weeks ago · accessnewswire.com

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

~ Productive FDA Meeting Highlights Path Toward Overdose Protection Labeling and 505(b)(2) Regulatory Strategy ~ ~ FDA and Ensysce Aligned on Collaborative Approach to Ensure Product's Full Safety Ben...

1 month ago · accessnewswire.com

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

~ FDA Protocol Review Completed ~ ~ Rho, Inc. Selected as Clinical Research Partner ~ SAN DIEGO, CA / ACCESS Newswire / July 16, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Compa...

1 month ago · accessnewswire.com

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

~ Treatment to Evaluate Effect of Food on Overdose Protection of MPAR ~ ~ Grant Funds from NIDA Accelerating Clinical Development Program ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 24, 2025 / En...

2 months ago · accessnewswire.com

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

~ Pain Management, RE-Invented: A New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / June 11, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharm...

2 months ago · accessnewswire.com

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

~ PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation ~ ~ Funds Accelerate Path Towards Commercialization ~ SAN DIEGO, CA / ACCESS Newswire / June 4, 2025 / Ensysce Biosciences...